Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart...

Area of Science:

• Cardiology
• Immunology
• Public Health

Background:

• Cardiovascular disease (CVD) patients face increased risks from influenza.
• Current influenza vaccination rates in CVD populations are suboptimal.
• Barriers include lack of vaccine availability in cardiology practices.

Purpose of the Study:

• To evaluate the impact of annual influenza vaccination on cardiovascular morbidity and mortality.
• To assess current vaccination coverage and identify barriers in CVD patients.
• To provide recommendations for improving influenza immunization in this population.

Main Methods:

• Review of cohort studies and a randomized clinical trial.
• Analysis of recommendations from major cardiology organizations.
• Assessment of vaccination coverage data and identified barriers.

Main Results:

• Annual influenza vaccination prevents cardiovascular morbidity and all-cause mortality in CVD patients.
• Inactivated influenza vaccine (intramuscular) is recommended; live attenuated vaccine (intranasal) is not.
• Vaccination coverage remains below national goals, with significant disparities.

Conclusions:

• Influenza immunization is a crucial component of secondary prevention for atherosclerotic vascular disease.
• Cardiology practices must stock and strongly recommend inactivated influenza vaccines.
• Improving vaccination rates requires proactive healthcare provider engagement and addressing access barriers.